Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition

Bristol Myers Squibb’s revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Revlimid.

from Health and Science https://ift.tt/BGRSpXb
https://ift.tt/kfIrZT4
https://ift.tt/qtLjmAk